Pazopanib shrinks lung cancers before surgery

September 17, 2008

Pazopanib, a new oral angiogenesis inhibitor, has demonstrated interesting activity in difficult to treat non-small-cell lung cancer, US researchers report.

In a phase II trial, 30 out of 35 patients treated with preoperative pazopanib for a minimum of two weeks saw their tumor size shrink by up to 85%.

"This is a positive result that will be explored further," said Prof. Nasser Altorki from Weil Medical College of Cornell University in New York.

"To my knowledge, no other results on the effect of angiogenesis inhibitors in early stage operable lung cancer have been published.

The results presented here with pazopanib indicate a highly active drug in this setting and further development in lung cancer is underway to fully understand the value of this drug in this disease."

European Society for Medical Oncology

---

---

	Kidney Cancer: Principles and Practice by Primo N. Lara Jr. (Editor), Eric Jonasch (Editor) This interdisciplinary textbook encompasses all clinically relevant aspects of the disease and is designed to be as user-friendly as possible in order to meet the needs of the busy practitioner. To this end, the informative text is complemented by helpful boxed sections that present essential ‘take home’ points and illustrative patient-oriented cases. Original high-quality images, some in color, are included whenever necessary to simplify particularly complex material. The authors are an international group of acknowledged experts in kidney cancer epidemiology, molecular biology, pathology, diagnosis, clinical features, staging, prognostic and predictive factors, surgery, systemic therapy, and emerging investigational approaches, among others. This clinically oriented volume will be...
	Kinase Inhibitor Drugs (Wiley Series in Drug Discovery and Development) by Rongshi Li (Author), Jeffrey A. Stafford (Author) A comprehensive resource on case studies of marketed kinase drugs and promising drug trialsSince the discovery of protein kinase activity in 1954, the field of protein kinase drug discovery has advanced dramatically. With the ongoing clinical success of the Bcr-Abl kinase inhibitor Gleevec in the treatment of chronic myelogenous leukemia and seven additional marketed kinase inhibitor drugs, researchers have compelling evidence that kinase inhibitors can be highly efficacious in the treatment of diseases caused by aberrant activity of protein kinase. Currently more than 100 protein kinase inhibitors are in clinical development.In one comprehensive volume, the editors, Dr. Rongshi Li and Dr. Jeffrey Stafford, present timely and important case studies of marketed kinase drugs and several of...
	Renal Cancer (Oxford Oncology Library) by Tim Eisen (Author) Renal cancer has recently become a very exciting area of oncology. Whilst it has been known for some time that individual patient outcomes vary greatly, therapeutic interventions for renal cancer have enjoyed only limited success until recently. In the past decade, there have been significant advances in surgical oncology which have only been matched by advances in new therapeutics within the last three years. Renal cancer is therefore a rapidly changing field, and investigators have had to learn novel ways of assessing disease, monitoring response to treatment and helping patients to cope with the side effects of these therapies. Part of the Oxford Oncology Library, this pocketbook summarises the latest evidence-based and practical information on the treatment of renal cancer. With...
	Gynecologic Cancer (Radiation Medicine Rounds) by Arno Mundt MD (Editor), Catheryn Yashar MD (Editor), Loren Mell MD (Editor), Charles R. Thomas Jr. MD (Editor) Radiation therapy is a major tool in the management of this family of cancers.. This issue of Radiation Medicine Rounds includes reviews of all major recent advances in treatment of gynecologic cancer. Articles also review current knowledge in the areas of biologic agents, Intensity Modulated Radiation Therapy, Image-Guided Brachytherapy, and robotic surgery in gynecologic cancer. This issue of RMR will provide the practitioner with a full current overview of the present best practices and recent research in management of this complex and challenging family of cancers. Radiation Medicine Rounds features: In-depth, up-to-date expert reviews and analysis of major new developments in all areas of Radiation Medicine Each issue edited by an authority in that subject area Each issue focused on...
	Modern Drug Synthesis by Jie Jack Li (Editor), Douglas S. Johnson (Editor) Following Contemporary Drug Synthesis and The Art of Drug Synthesis (Wiley, 2004 and 2007), two well-received works, is this new book that demystifies the process of modern drug discovery for practitioners and students. An enhanced introduction covers areas such as background, pharmacology, SAR, PK/PD, efficacy, and safety. Focusing on the advantages of process synthesis versus the discovery synthetic route, Modern Drug Synthesis features authoritative coverage by distinguished editors and authors (some chapter authors are the actual inventor of the drug) of twenty different drug molecules.
	Renal Cancer: ECT (Emerging Cancer Therapeutics V2 I1) by Walter Stadler MD (Editor), Jame Abraham MD (Editor) This issue of Emerging Cancer Therapeutics provides a comprehensive review for practitioners on the current status of renal cancer treatment. Renal cancer treatment has undergone major changes over the course of the past few years and Renal Cancer addresses current best practices in the light of the most recent evidence. All of the chapters are written by international experts in the field, address the common clinical scenarios in renal cancer and are multidisciplinary in scope covering surgical, medical, and radiation therapy. Chapters examining emerging and novel therapeutic targets, the management of both CNS, and skeletal metastases in renal cancer round out the coverage. Emerging Cancer Therapeutics features: Editorial board of nationally recognized experts across the spectrum of...
	Medikamentöse Tumortherapie in der Uroonkologie (German Edition) by Margitta Retz (Author), Jürgen E. Gschwend (Author) Das Arbeitsbuch vermittelt in knapper Form genau das Wissen, das ein urologischer Facharzt für die Prüfung zur Zusatzweiterbildung „Medikamentöse Tumortherapie" sowie für das Erstellen von Therapieplänen und die Therapie von Nebenwirkungen benötigt. Der Inhalt orientiert sich an den aktuellen Leitlinien und behandelt vor allem Wissensgebiete wie die Pharmakologie der Chemotherapeutika ein, die urologischen Fachärzten häufig nicht hundertprozentig geläufig sind. Mit Therapieschemata, Patientenaufklärungsbögen und Patiententagebuch "Target-Therapeutika" zum Kopieren.
	Dx/Rx: Genitourinary Oncology: Cancer Of The Kidneys, Bladder, And Testis by Matthew D. Galsky (Author) Designed For Oncologists, Urologists, And Any Other Health Professionals Who Care For Urologic Cancer Patients, Dx/Rx: Genitourinary Oncology: Cancer Of The Kidneys, Bladder, And Testis, Second Edition Is A Current, Concise, Quick Reference Guide To The Diagnosis And Therapy Genito-Urinary Cancers. Tightly Organized Into A Condensed Outline-Bulleted Format, This Pocket-Sized Reference Offers Precise And Up-To-Date Information On The Epidemiology, Classification, Diagnosis, Treatment, And Risk Factors For Cancers Of The Bladder/Urothelial Tract, Kidneys, And Testis. Throughout The Book, Tables And Figures Summarize Important Clinical Data And Current Professional Society Recommendations, While Salient References Direct Readers To Additional Information. The Second Edition Includes Three...
	Medifocus Guidebook on: Renal Cell Carcinoma by Medifocus.com Inc. (Author), Elliot Jacob PhD. (Editor) The MediFocus Guidebook on Renal Cell Carcinoma is the most comprehensive, up-to-date source of information available. You will get answers to your questions, including risk factors of Renal Cell Carcinoma, standard and alternative treatment options, leading doctors, hospitals and medical centers that specialize in Renal Cell Carcinoma, results of the latest clinical trials, support groups and additional resources, and promising new treatments on the horizon. This one of a kind Guidebook offers answers to your critical health questions including the latest treatments, clinical trials, and expert research; high quality, professional level information you can trust and understand culled from the latest peer-reviewed journals; and a unique resource to find leading experts, institutions, and...
	Oncology Studies in America: Cancer studies and trials underway in 2010 by Oystein Wergeland (Author) A catalog with a comprehensive and detailed list of all clinical cancer studies and trials currently being carried out in the United States and elsewhere. The list was compiled entirely from the website www.clinicaltrials.gov.